Journal of Antimicrobial Chemotherapy

Article	Citations
Correction to: Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomon	168
Low rates of complications and β-lactam resistance in viridans group streptococci bloodstream infection among cancer patients receiving chemotherapy	96
Correlation between rrs gene mutations and amikacin resistance in Mycobacterium abscessus: implications for fitness cost and clinical prevalence	93
Conventional versus extended-pulsed fidaxomicin dosing in patients at high risk of recurrence ofClostridioides difficileinfection: a propensity score analysis	87
Nephrotoxicity of continuous amphotericin B in critically ill patients with abdominal sepsis: a retrospective analysis with propensity score matching—authors’ response	75
Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus	68
Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis	68
Correction to: Phenotypic and genotypic analysis of antimicrobial resistance in Nocardia species	64
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit	63
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable	58
Off-label use of dalbavancin in children: a case series	57
Liposomal amikacin and Mycobacterium abscessus: intimate interactions inside eukaryotic cells	54
Comment on: A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections	54
Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudom	52
Neonatal sepsis due to NDM-1 and VIM-2 co-producing Pseudomonas aeruginosa in Morocco	49
Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery	47
Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus	45
Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection	44
Prosthetic joint infections: 6 weeks of oral antibiotics results in a low failure rate	43
Pharmacokinetics and pharmacogenetics of high-dosage tedizolid for disseminated nocardiosis in a lung transplant patient	43
Genomic insights into the tmexCD-toprJ : plasmid-mediated evolution, dissemination and diversity in bacterial populations	41
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study	40
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply	40
Fatal invasive pulmonary and cerebral aspergillosis due to triazole-resistant Aspergillus fumigatus with multiple CYP51A mutations	40
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study	40

Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients	39
Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study	39
Phenotypic and genotypic antimicrobial susceptibility patterns of the emerging human respiratory pathogen Mycoplasma amphoriforme isolated from the UK and Denmark	39
Epidemiology and clinical relevance of persistent bacteraemia in patients with Gram-negative bloodstream infection: a retrospective cohort study	37
Systematic review on oral antibacterial relay therapy for acute staphylococcal prosthetic joint infections treated with debridement, antibiotics and implant retention (DAIR)	36
Emergence of the mobile RND-type efflux pump gene cluster tmexCD1-toprJ1 in Klebsiella pneumoniae clinical isolates in Japan	36
Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics	36
Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions	35
Evaluation of the RESIST ACINETO multiplex immunochromatographic assay for detection of OXA-23-like, OXA-40/58-like and NDM carbapenemase production in Acinetobacter baumannii	34
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidate	34
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study	33
NDM-5-producing Klebsiella pneumoniae ST258 in a university hospital in Argentina	33
Ultra-rapid selection of the N74D capsid inhibitor resistance mutation after 3 weeks on lenacapavir	33
Exploring the pharmacokinetic mechanisms that affect bictegravir exposure during pregnancy	33
Molecular mechanism of envZ regulating β-lactam antibiotic resistance and virulence in Escherichia coli	32
SQ31f is a potent non-tuberculous mycobacteria antibiotic by specifically targeting the mycobacterial F-ATP synthase	32
Distinct molecular epidemiology of resistances to extended-spectrum cephalosporins and carbapenems in Enterobacter hormaechei in cats and dogs versus horses in France	32
Uropathogenic Escherichia coli population structure and antimicrobial susceptibility in Norfolk, UK	31
Engineering a CRISPR interference system targeting AcrAB-TolC efflux pump to prevent multidrug resistance development in Escherichia coli	31
Genomic and transcriptomic variation in Bordetella spp. following induction of erythromycin resistance	31
General practice antibiotic prescriptions attributable to respiratory syncytial virus by age and antibiotic class: an ecological analysis of the English population	31
The impact of palliative care consultation on reducing antibiotic overuse in hospitalized patients with terminal cancer at the end of life: a propensity score-weighting study	31
Point-of-care tests to manage acute respiratory tract infections in primary care: a systematic review and qualitative synthesis of healthcare professional and patient views	31
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights	30
Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with pipera	29
Characterization of a multiresistance optrA- and lsa(E)-harbouring unconventional circularizable structure in Streptococcus suis	29
Correction to: Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV	29
Antibiotic biocompatibility assay and anti-biofilm strategies for Pseudomonas aeruginosa infection in bioengineered artificial skin substitutes	28
Safety of topical tobramycin powder during operative treatment of fractures	28
Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis—authors’ response	28
Oral antimicrobial agents in patients with short bowel syndrome: worth a try!—authors’ response	28
Liver cyst penetration of antibiotics at the target site of infection: a randomized pharmacokinetic trial	28
External quality assurance (EQA) network in South and South-East Asia: experience and results from an international EQA programme in One Health sector reference laboratories	27
Comment on: Community-acquired pneumonia: a US perspective on the guideline gap	27
Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginos	27
Plasmodium falciparum isolates: ex vivo drug response	27
Streptococcus suisprophage lysin as a new strategy for combating streptococci-induced mastitis andStreptococcus suisinfection	27
Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre inf	27
Effect of different strategies for excluding duplicate cultures on the correlation between hospital resistance rates and antibiotic consumption	26
Genomic analysis reveals the population structure and antimicrobial resistance of avian Pasteurella multocida in China	26
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae	26
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates	26
Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children	25
Plasma concentration of orally administered amoxicillin and clindamycin in patients receiving haemodialysis	25
Synergistic effects of quorum-sensing molecules and antimicrobials against Candida albicans and Pseudomonas aeruginosa biofilms: in vitro and in vivo studies	25
Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?	25
Activity of mecillinam against carbapenem-resistant Enterobacterales	25
In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium	25
Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare	25
Reporting England’s progress towards the ambitions in the UK action plan for antimicrobial resistance: the English surveillance programme for antimicrobial utilisation and resistance (ESPAUR)	25

Assessment of co-resistance to antibiotics recommended for acute pyelonephritis among Escherichia coli clinical strains from community- and nursing home–acquired urinary tract infections	25
Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?	24
Investigating the cause of increased tetracycline-resistant Neisseria gonorrhoeae in England, 2016–20	24
Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia mod	24
Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions	24
Antibiotic-induced degradation of antitoxin enhances the transcription of acetyltransferase-type toxin-antitoxin operon	24
Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Türkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints	24
Effect of methenamine hippurate shortage on antibiotic prescribing for urinary tract infections in Norway—an interrupted time series analysis	24
Leveraging interdisciplinary management in people with HIV and lymphoid neoplasms	24
Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022	23
Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort	23
Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review	23
Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotlan	23
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge	23
A scoring system to predict resistance to ceftolozane/tazobactam in respiratory isolates of Pseudomonas aeruginosa	22
Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study	22
In vitro and in vivo antibacterial activity, resistance analysis and molecular docking study of pleuromutilin derivatives against Streptococcus suis	22
Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales	22
Subcutaneously administered antibiotics: a review (addendum)	22
Tn 7860 , a novel chromosomal pseudo-compound transposon carrying the OptrA gene in	22
Evaluation of fidaxomicin use in patients with a macrolide allergy/intolerance	22
Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study	22
Usefulness of inclusion of ertapenem and temocillin screening breakpoints in the EUCAST rapid antimicrobial susceptibility testing (RAST) for rapid detection of OXA-48-producing Klebsiella pneumoni	22
Pristinamycin-induced sideroblastic anaemia	22
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates	21
Temporal trends in antibiotic prescribing and serious and nonserious infections in children presenting to general practice: a registry-based longitudinal cohort study of 162 507 individuals	21
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry	21
Clinical aspects and recent advances in fungal diseases impacting human health	21
Correction to: Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant TB: a multicentre observational study from India	21
Surveillance of antimicrobial resistant Shiga toxin-producing E. coli O157:H7 in England, 2016–2020	21
Phenotypic and genotypic characterization of HMB-3, a metallo-beta-lactamase from Pseudomonas asiatica	21
Antibiotic use by clinical presentation across all healthcare providers in rural Burkina Faso: a healthcare visit exit survey	21
Decreased cyclic-AMP caused by ATP contributes to fosfomycin heteroresistance in avian Escherichia coli	21
GyrB in silico mining in 27 151 global gonococcal genomes from 1928–2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and	20
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using	20
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis	20
Stability of temocillin in outpatient parenteral antimicrobial therapy: is it a real option?	20
Validation of the Antifungal National Antimicrobial Prescribing Survey (AF-NAPS) quality assessment tool	20
Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing	20
Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example	20
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method	20
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions	20
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic	20
Diagnostic uncertainties in patients with bacteraemia: impact on antibiotic prescriptions and outcome	20
Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections	20
Prevalence of drug resistance mutations in low-level viremia patients under antiretroviral therapy in Southwestern China: a cross-sectional study	20
Swedish multicentre study of target attainments with β-lactams in the ICU: which MIC parameter should be used?	20
Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugs	20
Clinical, pharmacological, and qualitative characterization of drug–drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa	20
Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors	20
Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients	20
Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine	20
Population pharmacokinetics of aciclovir and its major metabolite 9-carboxymethoxymethylguanine and safety profile of valaciclovir in early liver transplant recipients	19
Off-label oritavancin treatment outcome and molecular characterization of a vancomycin- and linezolid-resistant Enterococcus faecium causing liver abscesses	19
Impact of veterinary antibiotics on plasmid-encoded antibiotic resistance transfer	19
The association between bacteriuria and adverse pregnancy outcomes: a systematic review and meta-analysis of observational studies	19
Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences	19
Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy	19
Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-	19
Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia	19
Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011–2020	19
Interventions to improve antibiotic use among dentists: a systematic review and meta-analysis	19
Temocillin efficacy against AmpC β-lactamase-producing Enterobacterales: a relevant alternative to cefepime?	19
The acquisition of transferable extrachromosomal fec operon is associated with a cefiderocol MIC increase in Enterobacterales	19
Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV	19
Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin Americ	19
Comment on: Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates	19
Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis	19
A multi-site, international laboratory study to assess the performance of penicillin susceptibility testing of Staphylococcus aureus	19
In vitro activity of fosfomycin against bacterial pathogens isolated from urine specimens in Canada from 2007 to 2020: CANWARD surveillance study	19
Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France	19
Population pharmacokinetics of bictegravir in real-world people with HIV	18
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database	18
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa	18
Genomic surveillance and antimicrobial resistance determinants in Neisseria gonorrhoeae isolates from Uganda, Malawi and South Africa, 2015–20	18
In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases	18
Establishment of RCPA national guidelines for selective reporting of antimicrobials: processes, challenges and measuring the impact	18
Influence of a putative TonB-dependent receptor on cefiderocol susceptibility in clinical Enterobacter hormaechei isolates	18
Preface	18
Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections	17

Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114	17
The antiplasmodial activity of the carboxylic acid metabolite of piperaquine and its pharmacokinetic profiles in healthy volunteers	17
Clinical impact of time to results from the microbiology laboratory in bloodstream infections caused by carbapenemase-producing Enterobacterales (TIME-CPE STUDY)	17
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients—authors’ response	17
Diffusion of amoxicillin into heart valves from infective endocarditis patients	17
The primary pharmacology of ceftazidime/avibactam: in vivo translational biology and pharmacokinetics/pharmacodynamics (PK/PD)	17
Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a	17
Correction to: In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program	17
Professor Alasdair Macintosh Geddes, 14 May 1934–9 April 2024	17
Correction to: Linezolid brain penetration in neurointensive care patients	17
Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints	17
In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates	16
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa	16
Raising awareness of antimicrobial resistance: development of an ‘antibiotic footprint calculator’	16
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes	16
Treatment of persistent focalized Q fever: time has come for an international randomized controlled trial	16
In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization	16
Correction to: Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal	16
Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up	16
Genomic characterization of colistin heteroresistance in Acinetobacter baumannii : Evidence for lpxD delet	16
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.	16
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study	16
Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient	16
Changing epidemiology of MRSA-CC398 in Spanish hospitals located in areas with different pig farming densities: a 2023 multicentre study	16
Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis?	16
Prevalence and associated factors of antibiotic exposure during pregnancy in a large French population-based study during the 2010–19 period	16
Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the	16
Carbapenem resistance in Enterobacterales bloodstream infections among children with cancer or post-haematopoietic stem cell transplant: a retrospective cohort study	16
Genomic comparison of mecC-carrying methicillin-resistant Staphylococcus aureus from hedgehogs and humans in the Netherlands	16
Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study	16
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy	16
Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach	16
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis	15
In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/	15
In vivo evaluation of cefazolin inoculum effect in the treatment of experimental Staphylococcus aureus pneumonia with cefazolin	15
Insights from the WHO Tricycle-aligned Fleming Fund EQASIA External Quality Assessment (EQA) programme detecting ESBL-, AmpC- and carbapenemase-producing Escherichia coli	15
Activity of rezafungin against Candida auris	15
Evaluation of an optimized intermittent vancomycin dosing regimen in infants	15
Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study i	15
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus	15
Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia	15
Antibiotic prescription patterns during last days of hospitalized patients with advanced cancer: the role of palliative care consultation	15
Gepotidacin: a novel, oral, ‘first-in-class’ triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea	15
A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19	15
Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023	15
Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018–22	15
The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study	15
Towards optimizing carbapenem selection in stewardship strategies: a prospective propensity score-matched study of ertapenem versus class 2 carbapenems for empirical treatment of third-generation ceph	15
Foreword	15
Emergence of mcr-8.1 gene coexisting with blaNDM in Citrobacter werkmanii isolated from a chicken farm in China	15
Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa	15
The veterinary clinic backyard lawn used for relief walks of hospitalized dogs is a hotspot for OXA-type carbapenemases in multiple Enterobacterales	15
Helicobacter pylori culture positivity and antimicrobial susceptibility profiles (Vancouver, Canada)	15
Identification of vancomycin exposure target in neonates: how much is enough?	15
Refractory versus resistant invasive aspergillosis	15
Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas a	15
JAC Supplement: ‘faster ID and AST revolution: how to improve antibiotic use in the critically ill’	15
In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa	15
Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective	14
Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli	14
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia	14
Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospit	14
Influence of factors commonly known to be associated with health inequalities on antibiotic use in high-income countries: a systematic scoping review	14
Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23	14
Correction to: Up-regulation of silent information regulator 2 (Sir2) is associated with amphotericin B resistance in clinical isolates of Leishmania donovani	14
Antimicrobial activity of aztreonam–avibactam against KPC variant-producing Klebsiella pneumoniae with ceftazidime–avibactam resistance	14
Rapid detection of CTX-M-type ESBLs and carbapenemases directly from biological samples using the BL-DetecTool	14
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius : the emergence of new epidemic waves across Europe, Asia and North America	14
Effect of albumin substitution on pharmacokinetics of piperacillin/tazobactam in patients with severe burn injury admitted to the ICU	14
In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species	14
Development and validation of a resazurin assay for in vitro susceptibility testing of Actinomadura madurae: a common causative agent of actinomycetoma	14
Fluoroquinolones in orthopaedic infection: balancing risks and rewards	14
Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa	14
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting	14
No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors	14
Association between antimicrobial usage in livestock and antimicrobial resistance in Escherichia coli isolates from human urinary tract infections in the Netherlands, 2009–2020	14
Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19)—authors’ response	14
Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models	14
Class 1 DISARM system in restriction of conjugative carbapenemase-encoding plasmids in Klebsiella pneumoniae sequence type 23	14
Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt	14
Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial	14
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study	14
Hospitalizations and severe complications following acute sinusitis in general practice: a registry-based cohort study	14
HIV-1 subtype F integrase polymorphisms external to the catalytic core domain contribute to severe loss of replication capacity in context of the integrase inhibitor resistance mutation Q148H	14
Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis	14
Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model againstKlebsiella pneumoniae—authors’ response	14
Association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015–16 to 2020–21 seasons: from the VENUS study	14
Comparison of prophylactic antibiotics for endonasal transsphenoidal surgery using a national inpatient database in Japan	14
Phenotypic and genetic characterization of antimicrobial resistance inSalmonella entericaserovar Choleraesuis isolates from humans and animals in Spain from 2006 to 2021	14
Depolymerase as a potent adjunct to polymyxin for targeting KL160 pandrug-resistant Acinetobacter baumannii in a murine bacteremia model	13
Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions	13
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae : a systematic review	13
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae	13
Molecular ecology of highest priority critically important antibiotic resistant Escherichia coli from mammals housed at an urban zoo	13
Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda	13